Monoclonal Antibody Reduces Asthma Attacks in Black and Latino Youth
A National Institutes of Health (NIH) clinical trial found that mepolizumab, a monoclonal antibody, decreased asthma attacks by 27% among Black and Latino children with severe asthma in low-income urban neighborhoods. These children are notably underrepresented in clinical trials of treatments for asthma, which is caused by chronic inflammation of the airways.